Ignite Creation Date:
2024-05-19 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06416410
Status:
RECRUITING
Last Update Posted:
2024-05-20
First Post:
2024-05-09
Brief Title:
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS pG12C Mutation
Sponsor:
Jacobio Pharmaceuticals Co Ltd
Organization:
Jacobio Pharmaceuticals Co Ltd
Study Overview
Official Title:
An Open-label Randomized Positive Control Multicenter Phase III Clinical Study Evaluating JAB-21822 Combined With JAB-3312 Compared Tislelizumab Combined With Pemetrexed Carboplatin in the First Line for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With KRAS pG12C Mutation
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Phase 3 study will evaluate the efficacy of JAB-21822JAB-3312 versus tislelizumab PD-1 Ab combined with pemetrexedcarboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None